HHS Secretary Robert F. Kennedy Jr. has issued an enforcement discretion policy allowing compounding pharmacies to produce and sell six specific peptide drugs, effectively overriding FDA scientists' safety concerns. The FDA had removed these peptides from allowable bulk drug substances in 2023 due to insufficient evidence of effectiveness and potential dangers.
Background
RFK Jr. serves as U.S. Health Secretary and is a prominent figure in the Make America Health Again (MAHA) movement, which has questioned established public health institutions. Compounding pharmacies create customized drug formulations outside standard FDA approval processes.
- Source
- Ars Technica
- Published
- Oct 29, 2026 at 06:17 AM
- Score
- 5.0 / 10